以上内容来自Benzinga Earnings专栏,原文如下:
Aytu BioPharma (NASDAQ:AYTU) reported quarterly losses of $(0.28) per share which met the analyst consensus estimate. This is a 600 percent decrease over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $16.22 million which beat the analyst consensus estimate of $15.55 million by 4.29 percent. This is a 29.27 percent decrease over sales of $22.93 million the same period last year.
精彩评论